Physician profile
William E Lyles
NPI 1750364782
$151,199.51
in general payments reported to CMS, 2019-2025
40 companies · $36K in 2025
The $36K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $8,346 · 2021: $11K · 2022: $20K · 2023: $13K · 2024: $54K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Food and Beverage: $10K · Travel and Lodging: $5,774 · Consulting Fee: $4,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,102.50 |
| Food and Beverage | $10,173.39 |
| Travel and Lodging | $5,774.03 |
| Consulting Fee | $4,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $98,253.16 | 2019-2025 | |
| Pfizer INC. | $29,030.69 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $13,977.99 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $1,851.44 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $1,296.41 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,188.91 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $1,187.39 | 2019-2023 | Spyglass, Exalt Model D |
| Intercept Pharmaceuticals, INC. | $402.48 | 2019-2023 | Ocaliva |
| Covidien Lp | $373.18 | 2019 | |
| Gilead Sciences, INC. | $345.27 | 2019-2025 | |
| Celgene Corporation | $333.48 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $318.51 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $207.88 | 2019-2024 | Linzess |
| Qol Medical, LLC | $202.64 | 2023-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $192.85 | 2019-2023 | Dificid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $191.08 | 2019-2025 | Injectafer |
| Ardelyx, INC. | $174.18 | 2023-2025 | Ibsrela |
| Shionogi INC | $134.13 | 2019 | |
| Ferring Pharmaceuticals INC. | $134.09 | 2019-2024 | Rebyota |
| Genzyme Corporation | $131.11 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $129.23 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $124.47 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $113.28 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $106.00 | 2025 | Rezdiffra |
| Novo Nordisk INC | $103.92 | 2022-2025 | Wegovy |
| Redhill Biopharma INC. | $89.18 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $85.37 | 2019 | |
| Evoke Pharma, INC. | $75.36 | 2022-2023 | Gimoti |
| Braintree Laboratories, INC. | $73.37 | 2019-2023 | Suflave, Sutab |
| Organon LLC | $68.31 | 2023-2024 | Hadlima, Renflexis |
| Allergan, INC. | $60.20 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $51.88 | 2023-2024 | Idacio |
| Ucb, INC. | $41.02 | 2019 | |
| Amgen INC. | $38.38 | 2021-2023 | Avsola, Amjevita |
| Biocompatibles, INC. | $23.14 | 2019 | |
| Qiagen, LLC | $19.85 | 2020 | |
| Shire North American Group INC | $18.96 | 2019 | |
| Alfasigma USA, INC. | $18.77 | 2020 | |
| Echosens North America, INC. | $18.17 | 2024 | Fibroscan |
| Capsovision, INC. | $13.78 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.